Faculdade de Ciências Agrárias e Veterinárias, UNESP/CPPAR, Via de Acesso Prof. Paulo Donatto Castellani, s/n CEP 14884-900, Jaboticabal, São Paulo, Brazil.
Faculdade de Ciências Agrárias e Veterinárias, UNESP/CPPAR, Via de Acesso Prof. Paulo Donatto Castellani, s/n CEP 14884-900, Jaboticabal, São Paulo, Brazil.
Exp Parasitol. 2014 Feb;137:14-20. doi: 10.1016/j.exppara.2013.11.007. Epub 2013 Dec 2.
The present study aimed to notify the history of albendazole sulphoxide (ALB-SO) and albendazole (ALBZ) efficacy against Taenia saginata cysticercus (Cysticercus bovis) parasitizing experimentally infected bovines. A total of 11 efficacy trials were performed between the years of 2002 and 2010. In order to perform these trials, animals were individually inoculated with 2×10(4) eggs of T. saginata in each study's day zero (D0). For every trial, a positive control group (untreated infected animals) and a negative control group (animals that were neither infected nor treated) were used. ALB-SO or ALB were administered in the different dosages, in different days of treatments. In a last study with this formulation, this active principle was administered orally, mixed with the mineral supplement, on the 60th DPI, in a dosage of 30mg/kg. In all trials, on the 100th DPI, all animals were euthanized and submitted to the sequenced slicing of 26 anatomical segments (fragments of approximately five millimeters) for the survey of T. saginata cysticercus. With the obtained results it is possible to verify that in the first trials, conducted in 2002, ALB-SO reached, independently of dosage and treatment scheme, efficacies superior to 98% (arithmetic means). The trials conducted in 2005 (2.5mg/kg on the 30th, 60th, and 90th DPI) obtained values of efficacy all inferior to 60%. In 2008, the trials with 2.5 and 7.7mg/kg demonstrated efficacy values inferior to 40%, for both dosages and treatment schemes (30th/60th/90th DPI and 60th DPI). When this formulation was administered orally on the dosage of 30mg/kg on the 60th DPI, the efficacy against T. saginata cysticercus reached 88.28%. ALB administered orally showed efficacy values of 0.0%, 29.88% and 28.64% in the dosages of 5, 10 and 15mg/kg, respectively, using the treatment schemes described above for each dosage. Based on the results of these trials, conducted in an eight year period (2002-2010) using the sequenced slicing method for evaluating the efficacy of the aforementioned formulations against T. saginata cysticercus, it is possible to observe that, amongst the few molecules used in the chemotherapic treatment against T. saginata larvae, ALB-SO, administered in varied routes, dosages and treatment schemes, the studies conducted in 2008, 2009, and 2010, have a low therapeutic efficacy against C. bovis in Brazil, while ALBZ had insignificant efficacy values against T. saginata larvae parasitizing experimentally infected bovines. However, future studies using molecular biology will be necessary to assess whether the difference on the efficacy of the ALB-SO can be related to strain or another specific factor.
本研究旨在介绍阿苯达唑亚砜（ALB-SO）和阿苯达唑（ALBZ）对寄生在实验感染牛体内的囊尾蚴（牛囊尾蚴）的疗效的历史。在 2002 年至 2010 年间进行了总共 11 项疗效试验。为了进行这些试验，动物在研究的第 0 天（D0）单独接种 2×10(4)个绦虫囊尾蚴的卵。对于每个试验，使用阳性对照组（未治疗的感染动物）和阴性对照组（既未感染也未治疗的动物）。以不同剂量、不同治疗天数给予 ALB-SO 或 ALB。在最后一项关于该制剂的研究中，该活性成分于第 60 天（DPI）口服给药，与矿物质补充剂混合，剂量为 30mg/kg。在所有试验中，于第 100 天（DPI），所有动物均被安乐死，并进行 26 个解剖段（约 5 毫米的片段）的连续切片，以调查牛囊尾蚴。根据获得的结果，可以验证在 2002 年进行的第一项试验中，ALB-SO 达到了独立于剂量和治疗方案的 98%以上的疗效（算术平均值）。2005 年进行的试验（第 30、60 和 90 天给予 2.5mg/kg）的疗效值均低于 60%。2008 年，使用 2.5 和 7.7mg/kg 的试验表明，两种剂量和治疗方案（第 30/60/90 天和第 60 天）的疗效值均低于 40%。当该制剂以 30mg/kg 的剂量口服给药时，对牛囊尾蚴的疗效达到 88.28%。在上述每个剂量的治疗方案中，使用口服给予的 5、10 和 15mg/kg 的 ALB 的疗效值分别为 0.0%、29.88%和 28.64%。基于在八年期间（2002-2010 年）进行的这些试验的结果，使用序列切片方法评估上述制剂对牛囊尾蚴的疗效，可以观察到，在用于治疗绦虫幼虫的少数几种分子中，ALB-SO 以不同的途径、剂量和治疗方案给药，在 2008 年、2009 年和 2010 年进行的研究表明，在巴西，ALB-SO 对 C. bovis 的治疗效果较低，而 ALBZ 对实验感染牛体内寄生的绦虫幼虫的疗效值微不足道。然而，需要进行未来的研究使用分子生物学来评估 ALB-SO 疗效的差异是否与株或其他特定因素有关。
